These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 8651045

  • 21. Long-term treatment with fenfluramine in obese subjects.
    Sensi S, Della Loggia F, Del Ponte A, Guagnano MT.
    Int J Clin Pharmacol Res; 1985; 5(4):247-53. PubMed ID: 4055167
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.
    Enzi G, Crepaldi G, Inelmen EM, Bruni R, Baggio B.
    Clin Neuropharmacol; 1988; 11 Suppl 1():S173-8. PubMed ID: 3052815
    [Abstract] [Full Text] [Related]

  • 26. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects.
    Kamphuis MM, Lejeune MP, Saris WH, Westerterp-Plantenga MS.
    Eur J Clin Nutr; 2003 Oct; 57(10):1268-74. PubMed ID: 14506488
    [Abstract] [Full Text] [Related]

  • 27. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R, Faulds D.
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [Abstract] [Full Text] [Related]

  • 28. Dexfenfluramine hydrochloride: an anorexigenic agent.
    Bever KA, Perry PJ.
    Am J Health Syst Pharm; 1997 Sep 15; 54(18):2059-72. PubMed ID: 9377205
    [Abstract] [Full Text] [Related]

  • 29. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun 15; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 30. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov 15; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM, Scott RS, Lintott CJ.
    Int J Obes Relat Metab Disord; 1994 Apr 15; 18(4):199-205. PubMed ID: 8044193
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr 15; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 36. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.
    McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G.
    Metabolism; 2001 Jul 15; 50(7):795-800. PubMed ID: 11436184
    [Abstract] [Full Text] [Related]

  • 37. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 15; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 38. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F, Lambert J, Rasio E, Serri O.
    Int J Obes Relat Metab Disord; 1993 Jan 15; 17(1):25-30. PubMed ID: 8383638
    [Abstract] [Full Text] [Related]

  • 39. [Judicious use of anorectics].
    Laurent-Jaccard A.
    Schweiz Rundsch Med Prax; 1991 Feb 05; 80(6):116-7. PubMed ID: 2003174
    [Abstract] [Full Text] [Related]

  • 40. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans.
    Fogteloo AJ, Pijl H, Frölich M, McCamish M, Meinders AE.
    Diabetes Nutr Metab; 2003 Apr 05; 16(2):109-14. PubMed ID: 12846450
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.